Phathom Pharmaceuticals began its Phase 2 pHalcon‑EoE‑201 study by dosing the first patient with VOQUEZNA (vonoprazan) for eosinophilic esophagitis (EoE). The study will enroll approximately 80 adults with endoscopically confirmed EoE and dysphagia.
Participants will receive 20 mg of VOQUEZNA once daily for 12 weeks, followed by a 12‑week open‑label extension in which all subjects receive the drug. The trial design includes a double‑blind, placebo‑controlled first phase and a subsequent open‑label extension to evaluate short‑term efficacy and longer‑term safety.
VOQUEZNA is a potassium‑competitive acid blocker approved in the United States for GERD and H. pylori infection. The EoE study represents a strategic expansion beyond its current indications and could support future pediatric programs, potentially extending the drug’s 10‑year New Chemical Entity exclusivity through May 3 2032.
Phathom’s Q3 2025 results showed net revenues of $49.5 million, up 25 % quarter‑over‑quarter, and a 43 % decline in operating expenses. The company updated its full‑year 2025 revenue guidance to $170–$175 million and reiterated its goal of achieving operating profitability in 2026 without additional equity financing.
Management highlighted the limited non‑steroidal treatment options for EoE and emphasized that VOQUEZNA’s acid suppression profile could provide an oral, non‑steroidal therapeutic alternative. The company expects top‑line primary and secondary results from the pHalcon‑EoE‑201 study in 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.